NLTX News and Press, Neoleukin Therapeutics Inc. From 03/18/21

SEATTLE, March 18, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced it will report full year 2020 financial re...

SEATTLE, March 02, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Execut...

SEATTLE, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executi...

Neoleukin is a leader in de novo drug design. The company's lead asset was recently put on clinical hold, pending more dosing data, creating a window to buy the stock. The company has the platform potential to expand their pipeline to a wide-range of protein therapeutics for cancer an...

Neoleukin Therapeutics (NASDAQ: NLTX) , a clinical-stage biopharmaceutical company, is not ending the week on a positive note. Shares of the drugmaker are dropping sharply on Friday and are down by 10.9% as of 12:33 p.m. EST, after plunging by as much as 21.7% earlier today. The cat...

Gainers: Chimerix (CMRX) +59%. Jaguar Health (JAGX) +36%. Medigus (MDGS) +23%. Merus (MRUS) +22%. SCWorx (WORX) +20%.Losers: Sarepta Therapeutics (SRPT) -50%. SOS (SOS) -42%. Neoleukin Therapeutics (NLTX) -15%. Bionano Genomics (BNGO) -14%. Solid Biosciences (SLDB) -12%. For furth...

Sarepta Therapeutics (SRPT) -48% as DMD gene therapy treatment fails to meet primary endpoint.Neoleukin Therapeutics (NLTX) -19% after receiving clinical hold letter from FDA related to CMC assay development for NL-201.Solid Biosciences (SLDB) -18% after Sarepta ...

Neoleukin Therapeutics (NLTX) drops ~20% in premarket trading after receiving a clinical hold from the FDA related to its Investigational New Drug ((IND)) application to start a Phase 1 program of its immunotherapeutic candidate, NL-201.The FDA has asked the company to develop a new...

SEATTLE, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that on January 7, 2021, it received a clin...

SEATTLE, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief E...